FDA PMA: Premarket Approval & Submission Guide
Last reviewed:
Premarket Approval (PMA) is the FDA’s most rigorous regulatory pathway for medical devices and is required for Class III devices. PMA submissions undergo rigorous FDA review and demand significant time and resources to prepare.
Video guide
FDA PMA: Premarket Approval Explained
Learn when a device may need FDA premarket approval and how PMA evidence, fees and review clocks fit together.
Open video pageTranscript (English)
When does a device need a PMA? Usually when it is Class III, and FDA must approve it before it is marketed. Here is the cost and the clock. For fiscal year 2027, which began on October 1, an original PMA carries a user fee of $636,732. A qualified small business pays $159,183, and one with sales of $30 million or less may have its first PMA fee waived. A PMA does not rest on a predicate. FDA approves it on sufficient valid scientific evidence that the device itself is safe and effective for its intended use, usually from lab studies and clinical investigations. The regulation sets the clock: 45 days to decide on filing, then a 180-day review from the filing date. A major amendment can add up to 180 days. Start with three things. One: confirm a PMA is required for your product code. Two: get FDA feedback on your study plan. Three: apply for small business status 60 days ahead. Build the evidence before the filing. Pure Global covers registration, in-country representation, quality systems, audits and cybersecurity, in more than 30 markets. Visit pureglobal.com.
FDA Premarket Approval: when PMA applies
Premarket Approval (PMA) is the US FDA pathway generally required for Class III device types subject to PMA requirements. The applicant must provide valid scientific evidence supporting reasonable assurance of safety and effectiveness for the proposed use. PMA is not based on substantial equivalence to a predicate.
Confirm the classification regulation and applicable FDA decisions. Novel low- or moderate-risk products may qualify for De Novo; lack of a predicate alone does not mean PMA. Some historically classified device types have specific pathway rules. Read the actual regulation rather than relying on risk shorthand.
PMA versus 510(k) and De Novo
| Pathway | Central argument | Outcome |
|---|---|---|
| 510(k) | Substantial equivalence to an eligible predicate | Clearance |
| De Novo | New device type can be adequately controlled as Class I or II | Classification grant |
| PMA | Scientific safety/effectiveness evidence for the device and proposed indications | Approval |
The clinical, nonclinical and manufacturing evidence must match the device’s claims, configuration and risk. Plan clinical endpoints and statistical analyses before executing the study; use an FDA Pre-Submission when feedback can resolve a material uncertainty.
What belongs in a PMA program?
Prepare the device description, indications, nonclinical and clinical evidence, benefit-risk analysis, manufacturing information, quality-system evidence and labeling. Depending on the device, this can involve bench testing, biocompatibility, sterilization, software, cybersecurity and human-factors work. Document test articles, methods, deviations and the connection between results and claims.
Assign owners to the clinical database, manufacturing descriptions and submission sections. Freeze the configuration used to support the filing and assess changes systematically. A modular PMA can allow review of agreed parts before the entire application is ready, but it requires a suitable development and submission plan.
Review stages and calendar planning
FDA’s PMA review process includes acceptance/filing review and substantive evaluation. Advisory-panel review can be part of the process; it is not a mandatory stage for every PMA. Manufacturing compliance and inspection work are assessed as applicable rather than promised as one identical inspection sequence for every applicant.
The statutory 180-day review framework is not a guarantee of an approval within 180 calendar days. Filing status, deficiencies, applicant responses, clinical work, panel considerations and applicable performance goals affect the total program. Track FDA review time separately from applicant evidence-generation time.
For FY 2027, October 1, 2026–September 30, 2027, the official fee schedule lists an original PMA fee of US$636,732, or US$159,183 for a qualified small business. Additional program qualifications and waivers may apply. Confirm the current determination and application category before payment; annual establishment and applicable periodic-report fees are separate.
Submission format and changes after approval
FDA offers eSTAR voluntarily for supported PMA applications and supplements. Follow the receiving center’s current delivery instructions rather than assuming every PMA uses the same gateway. Preserve a controlled copy of every submitted version and response.
| Change category | Common route to assess | Key decision |
|---|---|---|
| New indication or major clinical change | Panel-track or other appropriate supplement | Required clinical evidence and approval before implementation |
| Design, labeling or manufacturing change affecting safety/effectiveness | Appropriate PMA supplement, potentially 180-day or real-time | Eligibility depends on the change and supporting information |
| Certain manufacturing-method changes | 30-day notice where eligible | FDA can require a different review route |
| Other reportable changes | Applicable periodic reporting | Confirm the reporting rule; do not assume every minor change is exempt |
Use FDA’s supplement and amendment instructions for the actual category. Maintain QMSR, registration/listing, MDR reporting and approval conditions throughout the lifecycle. Pure Global can coordinate pathway planning, evidence readiness, filing and post-approval change assessment.
Expert Guidance for FDA PMA Success
Plan your device registration, local representation and ongoing compliance with Pure Global.

Frequently asked questions
No. Advisory-panel review is used when applicable to the particular application. FDA’s review plan depends on the device, evidence and issues requiring expert input; a panel is not a universal PMA stage.
The statutory review framework and applicable FDA performance goals do not guarantee approval within that calendar period. Filing issues, applicant response holds, additional studies and other review work can extend elapsed time.
Assess the change under the PMA supplement and reporting rules before implementation. Design, labeling, indication and manufacturing changes can require different supplement, notice or reporting routes depending on their impact.
Single Process,
Multiple Markets
When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.
Let's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us










